$SURG
SurgePays, Inc. Stock $surg

$surg Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224009661 Filed on March 12, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$31.43M	$32.32M	$137.1M
YoY Change	-9.63%	-10.79%	12.83%
Cost Of Revenue	$23.25M	$24.88M	$101.5M
YoY Change	-14.16%	-15.68%	-6.08%
Gross Profit	$8.183M	$7.442M	$35.64M
YoY Change	6.34%	10.67%	164.62%
Gross Profit Margin	26.04%	23.03%	25.99%
Selling, General & Admin	$6.431M	$6.309M	$15.71M
YoY Change	115.12%	116.59%	22.42%
% of Gross Profit	78.59%	84.78%	44.09%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$70.38K	$266.0K	$1.064M
YoY Change	0.0%	-1.05%	280.2%
% of Gross Profit	0.86%	3.57%	2.99%
Operating Expenses	$6.431M	$6.575M	$16.78M
YoY Change	115.12%	106.77%	30.71%
Operating Profit	$1.752M	$866.3K	$18.87M
YoY Change	-62.77%	-75.56%	2876.62%
Interest Expense	-$116.4K	-$102.5K	-$485.8K
YoY Change	-129.11%	-80.3%	-221.45%
% of Operating Profit	-6.65%	-11.83%	-2.57%
Other Income/Expense, Net	-$116.4K		-$485.8K
YoY Change	-26.91%		-59.08%
Pretax Income	$1.635M	$763.8K	$18.38M
YoY Change	-64.02%	-77.13%	-3422.24%
Income Tax	$423.0K	-$2.265M	-$2.265M
% Of Pretax Income	25.86%	-296.56%	-12.32%
Net Earnings	$1.225M	$3.021M	$20.62M
YoY Change	-73.06%	-0.77%	-3128.65%
Net Earnings / Revenue	3.9%	9.35%	15.03%
Basic Earnings Per Share	$0.07		$1.45
Diluted Earnings Per Share	$0.07	$0.20	$1.38
COMMON SHARES
Basic Shares Outstanding	19.29M shares	14.23M shares	14.26M shares
Diluted Shares Outstanding	18.68M shares		14.92M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$42.95M	$14.62M	$14.62M
YoY Change	384.59%	107.83%	107.83%
Cash & Equivalents	$42.95M	$14.62M	$14.62M
Short-Term Investments
Other Short-Term Assets	$499.9K	$161.9K	$161.9K
YoY Change	194.15%	45.2%	45.2%
Inventory	$7.344M	$9.047M	$9.047M
Prepaid Expenses	$499.9K	$161.9K
Receivables	$8.272M	$9.536M	$9.536M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$59.06M	$33.37M	$33.37M
YoY Change	72.62%	21.05%	21.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$291.5K	$1.289M	$1.289M
YoY Change	-49.13%	100.37%	-11.82%
Goodwill	$4.167M	$1.667M
YoY Change	149.99%	0.0%
Intangibles	$1.963M	$2.126M
YoY Change	-24.98%	-23.51%
Long-Term Investments	$480.6K	$464.4K	$464.4K
YoY Change	24.1%	31.11%	31.11%
Other Assets	$2.542M	$2.835M	$2.835M
YoY Change
Total Long-Term Assets	$10.52M	$8.559M	$8.559M
YoY Change	65.66%	32.9%	32.9%
TOTAL ASSETS
Total Short-Term Assets	$59.06M	$33.37M	$33.37M
Total Long-Term Assets	$10.52M	$8.559M	$8.559M
Total Assets	$69.59M	$41.93M	$41.93M
YoY Change	71.53%	23.3%	23.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.070M	$7.487M	$7.487M
YoY Change	-7.07%	-0.34%	-0.34%
Accrued Expenses	$94.24K	$43.14K	$43.14K
YoY Change	133.38%	9.24%	9.24%
Deferred Revenue
YoY Change
Short-Term Debt	$1.567M	$4.585M	$4.585M
YoY Change	-30.02%	72.99%	72.99%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.432M	$12.71M	$12.71M
YoY Change	-63.22%	-45.85%	-45.85%
LONG-TERM LIABILITIES
Long-Term Debt	$3.625M	$460.5K	$460.5K
YoY Change	-20.32%	-90.83%	-90.83%
Other Long-Term Liabilities	$342.4K	$356.3K	$356.3K
YoY Change	-11.96%	-10.8%	-10.8%
Total Long-Term Liabilities	$3.968M	$816.8K	$816.8K
YoY Change	-19.66%	-84.93%	-84.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.432M	$12.71M	$12.71M
Total Long-Term Liabilities	$3.968M	$816.8K	$816.8K
Total Liabilities	$13.40M	$13.68M	$13.68M
YoY Change	-56.19%	-52.65%	-52.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$13.96M	-$15.19M
YoY Change	-55.33%	-57.59%
Common Stock	$19.44K	$14.40K
YoY Change	37.09%	2.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$56.04M	$28.25M	$28.25M
YoY Change
Total Liabilities & Shareholders Equity	$69.59M	$41.93M	$41.93M
YoY Change	71.53%	23.3%	23.3%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$1.225M	$3.021M	$20.62M
YoY Change	-73.06%	-0.77%	-3128.65%
Depreciation, Depletion And Amortization	$70.38K	$266.0K	$1.064M
YoY Change	0.0%	-1.05%	280.2%
Cash From Operating Activities	$4.040M	$1.958M	$10.29M
YoY Change	40.98%	-58.74%	1196.83%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$281.3K
YoY Change	-100.0%	-100.0%	-76.31%
Cash From Investing Activities		$0.00	-$281.3K
YoY Change		-100.0%	-81.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$207.2K
YoY Change
Debt Paid & Issued, Net	$2.870K		$14.32K
YoY Change			21.86%
Cash From Financing Activities	$24.28M	-67.04K	-2.420M
YoY Change	-2852.17%	-98.71%	-266.02%
NET CHANGE
Cash From Operating Activities	$4.040M	1.958M	10.29M
Cash From Investing Activities		0.000	-281.3K
Cash From Financing Activities	$24.28M	-67.04K	-2.420M
Net Change In Cash	$28.32M	1.891M	7.586M
YoY Change	1450.73%	-320.76%	908.62%
FREE CASH FLOW
Cash From Operating Activities	$4.040M	$1.958M	$10.29M
Capital Expenditures
Free Cash Flow			$10.29M
YoY Change			1215.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvested		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001392694
CY2022Q4	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent		usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		usd
CY2023Q4	SURG	Installment Sale Liability InstallmentSaleLiability		usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	SURG	Gain On Forgiveness Of Ppp Loan Government GainOnForgivenessOfPppLoanGovernment		usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	SURG	Conversion Of Preferred Stockto Common Stock Related Parties ConversionOfPreferredStocktoCommonStockRelatedParties		usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022	SURG	Stock Issued During Period Value Exercise Of Warrants Cashless StockIssuedDuringPeriodValueExerciseOfWarrantsCashless		usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2022	SURG	Amortization Of Internal Use Software Development Costs AmortizationOfInternalUseSoftwareDevelopmentCosts		usd
CY2022	SURG	Recognition Of Stock Based Compensation Unvested Shares Related Party RecognitionOfStockBasedCompensationUnvestedSharesRelatedParty		usd
CY2023	SURG	Warrants Issued For Interest Expense WarrantsIssuedForInterestExpense		usd
CY2023	SURG	Gain On Forgiveness Of Ppp Loan GainOnForgivenessOfPppLoan		usd
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes		usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable		usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware		usd
CY2023	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction		usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1		usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares		shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue		usd
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable		usd
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvested		usd
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested		shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsUnvested
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvested		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueGranted
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested		shares
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsUnvested
CY2023Q4	SURG	Installment Sale Liability InstallmentSaleLiability		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Federal State And Local Income Tax Expense Benefit Continuing Operations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2022	us-gaap	Federal State And Local Income Tax Expense Benefit Continuing Operations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2023	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	SURG	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation		usd
CY2022Q4	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40992
CY2023	dei	Entity Registrant Name EntityRegistrantName	SURGEPAYS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0550352
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3124 Brother Blvd
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 104
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Bartlett
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	38133
CY2023	dei	City Area Code CityAreaCode	901
CY2023	dei	Local Phone Number LocalPhoneNumber	302-9587
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19290799	shares
CY2023Q2	dei	Entity Public Float EntityPublicFloat	62587072	usd
CY2023	dei	Auditor Firm AuditorFirmId	910
CY2023	dei	Auditor Name AuditorName	Rodefer Moss & Co, PLLC
CY2023	dei	Auditor Location AuditorLocation	Johnson City, Tennessee
CY2023Q4	us-gaap	Cash Cash	14622060	usd
CY2022Q4	us-gaap	Cash Cash	7035654	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9536074	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9230365	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9046594	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	11186242	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	161933	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	111524	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	33366661	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	27563785	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	361841	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	643373	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2126470	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2779977	usd
CY2023Q4	SURG	Internal Use Software Development Costs Net InternalUseSoftwareDevelopmentCostsNet	539424	usd
CY2022Q4	SURG	Internal Use Software Development Costs Net InternalUseSoftwareDevelopmentCostsNet	387180	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1666782	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1666782	usd
CY2023Q4	us-gaap	Investments Investments	464409	usd
CY2022Q4	us-gaap	Investments Investments	354206	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	387869	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	431352	usd
CY2023Q4	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent	2835000	usd
CY2023Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	8196805	usd
CY2022Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	5796348	usd
CY2023Q4	us-gaap	Assets Assets	41925307	usd
CY2022Q4	us-gaap	Assets Assets	34003506	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	570000	usd
CY2022Q4	SURG	Installment Sale Liability InstallmentSaleLiability	13018184	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	20000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	243110	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	43137	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39490	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12705044	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23464062	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	356276	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	399413	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	816799	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5421191	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13521843	usd
CY2022Q4	us-gaap	Liabilities Liabilities	28885253	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14403261	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14403261	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14116832	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14116832	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	14404	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	14117	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43421019	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40780707	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15186203	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35804106	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	28249220	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4990718	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	154244	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	127535	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28403464	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5118253	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41925307	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34003506	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	137141832	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	121544190	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	101499341	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	108074782	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16777107	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12835623	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	118276448	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	120910405	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	18865384	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	633785	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	595975	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	1843396	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	110203	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-89082	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	115404	usd
CY2022	SURG	Gain On Forgiveness Of Ppp Loan Government GainOnForgivenessOfPppLoanGovernment	524143	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	336726	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-485772	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1187013	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	18379612	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-553228	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2265000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	20644612	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-553228	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	26709	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	127535	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	20617903	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-680763	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.45
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.38
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14258172	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12395364	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14922881	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12395364	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5118253	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1290024	usd
CY2023	SURG	Adjustments To Additional Paid In Capital Share Based Compensation Unvested Shares Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationUnvestedSharesRequisiteServicePeriodRecognition	529534	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	576625	usd
CY2023	SURG	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Related Party Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRelatedPartyRequisiteServicePeriodRecognition	37176	usd
CY2023	SURG	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	207240	usd
CY2023	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	26709	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	20617903	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28403464	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3551321	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3551321	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1086413	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	103500	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	37176	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	411400	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	115404	usd
CY2022	SURG	Adjustments To Additional Paid In Capital Warrant Issued Warrants Issued As Interest Expense AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWarrantsIssuedAsInterestExpense	365794	usd
CY2022	SURG	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	473	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	127535	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-680763	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-680763	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5118253	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5118253	usd
CY2023	us-gaap	Profit Loss ProfitLoss	20644612	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-553228	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	90009	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-59485	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	51718	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	935039	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	933384	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	43483	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	55316	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	115404	usd
CY2023	SURG	Amortization Of Internal Use Software Development Costs AmortizationOfInternalUseSoftwareDevelopmentCosts	129060	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1290024	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	103500	usd
CY2023	SURG	Recognition Of Stock Based Compensation Unvested Shares Related Party RecognitionOfStockBasedCompensationUnvestedSharesRelatedParty	529534	usd
CY2022	SURG	Warrants Issued For Interest Expense WarrantsIssuedForInterestExpense	365794	usd
CY2023	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	110203	usd
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-89082	usd
CY2022	SURG	Gain On Forgiveness Of Ppp Loan GainOnForgivenessOfPppLoan	524143	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	395718	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5920991	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2139648	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6878664	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	50409	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	111524	usd
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	2835000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-33140	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-39490	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-49352	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10287345	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	793272	usd
CY2023	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	570000	usd
CY2023	SURG	Increase Decrease In Installment Sale Liability Net IncreaseDecreaseInInstallmentSaleLiabilityNet	-13018184	usd
CY2022	SURG	Increase Decrease In Installment Sale Liability Net IncreaseDecreaseInInstallmentSaleLiabilityNet	13018184	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-223110	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11402	usd
CY2023	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	281304	usd
CY2022	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	387180	usd
CY2022	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	300000	usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	800000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-281304	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1498582	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	207240	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	473	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1017385	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	6700000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1595167	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5231251	usd
CY2023	SURG	Repayments Of Short Term Debt Including Notes Payable RepaymentsOfShortTermDebtIncludingNotesPayable	14323	usd
CY2022	SURG	Repayments Of Short Term Debt Including Notes Payable RepaymentsOfShortTermDebtIncludingNotesPayable	11754	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2419635	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1457468	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7586406	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	752158	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7035654	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6283496	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14622060	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7035654	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	222326	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	523005	usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	115404	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	411400	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	20617903	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10287345	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15186203	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28403464	usd
CY2023Q4	SURG	Working Capital WorkingCapital	20661617	usd
CY2023Q4	us-gaap	Cash Cash	14622060	usd
CY2023	us-gaap	Reimbursement From Limited Partnership Investment ReimbursementFromLimitedPartnershipInvestment	100	usd
CY2023	SURG	Reimbursement Cost Per Customer ReimbursementCostPerCustomer	30	usd
CY2023	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	0	usd
CY2022	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	1679723	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1666782	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1666782	usd
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q4	SURG	Notes Receivable Gross Due In Next Twelve Months NotesReceivableGrossDueInNextTwelveMonths	141759	usd
CY2023Q4	SURG	Notes Receivable Gross Due In Year Two NotesReceivableGrossDueInYearTwo	44766	usd
CY2023Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	186525	usd
CY2023Q4	SURG	Less Interest Receivable LessInterestReceivable	9674	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2023Q4	SURG	Notes Receivable Gross Due NotesReceivableGrossDue	52227	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zpxrUiHFRPja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z87MelChGkF6">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates during the years ended December 31, 2023 and 2022, respectively, include, allowance for doubtful accounts and other receivables, inventory reserves and classifications, valuation of loss contingencies, valuation of stock-based compensation, estimated useful lives related to intangible assets, capitalized internal-use software development costs, and property and equipment, implicit interest rate in right-of-use operating leases, uncertain tax positions, income tax payable and the valuation allowance on deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	17525	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	17525	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	51718	usd
CY2023	SURG	Proceeds From Purchase Of Inventory ProceedsFromPurchaseOfInventory	2411445	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9046594	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	11186242	usd
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	20000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	243110	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	137141832	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	121544190	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	570000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	110203	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-89082	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	152851	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	259393	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-2973543	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2126470	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2779977	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	653507	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	653507	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5690427	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5688193	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	20617903	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-680763	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14258172	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12395364	shares
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	664709	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14922881	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12395364	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.45
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.38
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	166356	usd
CY2022	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	20125153	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zMEks5jXeudd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zc2Mv794kf6b">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no material effect on the consolidated results of operations, stockholders’ equity, or cash flows.</span></p>
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1006286	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1006286	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	82752	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	82752	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1089038	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1089038	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	727197	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	445665	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	361841	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	643373	usd
CY2022Q2	us-gaap	Property Plant And Equipment Fair Value Disclosure PropertyPlantAndEquipmentFairValueDisclosure	711400	usd
CY2022Q2	us-gaap	Payments For Software PaymentsForSoftware	300000	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	85000	shares
CY2022Q2	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	411400	usd
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.84
CY2023	us-gaap	Depreciation Depreciation	281532	usd
CY2022	us-gaap	Depreciation Depreciation	279877	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5753520	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5753520	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-3627050	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	653507	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	653507	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	653507	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	165949	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2126470	usd
CY2023	SURG	Amortization Of Internal Use Software Development Cost AmortizationOfInternalUseSoftwareDevelopmentCost	129060	usd
CY2022	SURG	Amortization Of Internal Use Software Development Cost AmortizationOfInternalUseSoftwareDevelopmentCost	0	usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1131185	usd
CY2022	SURG	Forgiveness Of Loan ForgivenessOfLoan	-518167	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	11754	usd
CY2022	SURG	Long Debt Reclassified To Receivable LongDebtReclassifiedToReceivable	-126418	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	474846	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	14323	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	460523	usd
CY2022	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	524143	usd
CY2021	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	377743	usd
CY2021	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	Monthly payments are $3,566/month
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	4584563	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	460523	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	5045086	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	43483	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	34294	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	20804	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	11598	usd
CY2023	us-gaap	Lease Cost LeaseCost	64287	usd
CY2022	us-gaap	Lease Cost LeaseCost	45892	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	39490	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	30948	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y11M26D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	61876	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	73460	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	65044	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	66627	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	100246	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	107261	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	474514	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	75101	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	399413	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	43137	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	356276	usd
CY2021Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	73000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Voting at 1 vote per share
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1400000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4900000	shares
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	242615	shares
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1290024	usd
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedGrantsInPeriodGross	695000	shares
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Non Vested Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M26D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	695000	shares
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Non Vested Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M26D
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3103967	usd
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAveragePeriod	P1Y2M23D
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	200000	shares
CY2022	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	0	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	711400	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	300000	usd
CY2022	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	85000	shares
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	411400	usd
CY2022Q4	us-gaap	Share Price SharePrice	4.84
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17004	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M28D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3401	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.00
CY2021	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P5Y1M28D
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Un Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnVestedAndExercisableNumber	13603	shares
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Nonexercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonexercisable	16.00
CY2021	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P5Y1M28D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17004	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M28D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6801	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.00
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P4Y1M28D
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Un Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnVestedAndExercisableNumber	10203	shares
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Nonexercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonexercisable	16.00
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P0Y10M9D
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue	9348348	usd
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5574253	shares
CY2023Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	4.81
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P0Y10M9D
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable	9348348	usd
CY2022	us-gaap	Notes Issued1 NotesIssued1	1700000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	51000	shares
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P4Y1M28D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	104272	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.45
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	5.53
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	121276	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.79
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	116174	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.43
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P6Y7M9D
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Un Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnVestedAndExercisableNumber	5101	shares
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Nonexercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonexercisable	16.00
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P3Y1M28D
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	613801	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	37176	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6082984	shares
CY2021Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	8.68
CY2021	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P2Y11M4D
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5852984	shares
CY2021Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	8.70
CY2021	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P2Y10M6D
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested	230000	shares
CY2021Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested	8.00
CY2021	SURG	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsUnvested	P4Y10M6D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	189000	shares
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueGranted	4.73
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	498850	shares
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercise SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercise	6.49
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	91743	shares
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Forfeitured SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueForfeitured	40.02
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5681392	shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	5.05
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P1Y10M6D
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue	10026387	usd
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5681392	shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	5.05
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P1Y10M6D
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable	10026387	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	43814	shares
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercise SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercise	4.73
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	63325	shares
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Forfeitured SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueForfeitured	26.39
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5574253	shares
CY2023Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	4.81
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	115404	usd
CY2023	us-gaap	Revenues Revenues	137141832	usd
CY2022	us-gaap	Revenues Revenues	121544190	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	101499341	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	108074782	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	16777107	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	12835623	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	18865384	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	633785	usd
CY2023Q4	us-gaap	Assets Assets	41925307	usd
CY2022Q4	us-gaap	Assets Assets	34003506	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13521843	usd
CY2022Q4	us-gaap	Liabilities Liabilities	28885253	usd
CY2023Q4	us-gaap	Assets Net AssetsNet	0	usd
CY2022	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	25000000	usd
CY2022	SURG	Sales Of Asset Description SalesOfAssetDescription	The agreement could be extended by a period of one (1) year upon mutual consent.
CY2022Q4	SURG	Sales Of Asset Percentage SalesOfAssetPercentage	0.0985	pure
CY2022	SURG	Installment Sale Credit Description InstallmentSaleCreditDescription	3 month rolling average of 70% of the installment sale credit amount.
CY2022	SURG	Prepayment Penalty Description PrepaymentPenaltyDescription	The Company was subject to a cancellation fee of 3% during the first year and 2% during the second year
CY2022	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	2000	usd
CY2022	SURG	Default Rate Description DefaultRateDescription	For any unpaid amounts under this agreement, the Company was subject to a fee of 1.35% per month (16.2% annualized).
CY2022	us-gaap	Line Of Credit Facility Commitment Fee Percentage LineOfCreditFacilityCommitmentFeePercentage	0.02	pure
CY2022	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	5000000	usd
CY2022	us-gaap	Line Of Credit Facility Commitment Fee Description LineOfCreditFacilityCommitmentFeeDescription	For example, if the initial installment sale credit amount is $15,000,000, the credit availability fee would be $300,000 (2%). Any subsequent increase of $5,000,000 or more would result in an additional fee of $100,000 (2%). Commitment fees are paid over a period of 12 months as part of the Seller’s monthly invoicing.
CY2022Q4	SURG	Installment Sale Liability InstallmentSaleLiability	13018184	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	491536	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	1499007	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	570000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2835000	usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-2265000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.1964	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3848000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-134000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.1964	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3848000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-134000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.065	pure
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	923000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-44000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-137000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	174000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	138000	usd
CY2023	SURG	Income Tax Expense Benefit Subtotal IncomeTaxExpenseBenefitSubtotal	4945000	usd
CY2022	SURG	Income Tax Expense Benefit Subtotal IncomeTaxExpenseBenefitSubtotal	-177000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-7210000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	177000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2265000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.1236	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2023Q4	SURG	Reserve For Uncollectible Accounts ReserveForUncollectibleAccounts	5000	usd
CY2022Q4	SURG	Reserve For Uncollectible Accounts ReserveForUncollectibleAccounts	5000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3844000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	8000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3849000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8005000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	790000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8005000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	3059000	usd
CY2023Q4	SURG	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	224000	usd
CY2023Q4	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent	2835000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7619000	usd

Files In Submission

Name	View Source	Status
R42.htm	Edgar Link	pending
0001493152-24-009661-index-headers.html	Edgar Link	pending
0001493152-24-009661-index.html	Edgar Link	pending
0001493152-24-009661.txt	Edgar Link	pending
0001493152-24-009661-xbrl.zip	Edgar Link	pending
ex10-25.htm	Edgar Link	pending
ex19-1.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
surg-20231231.xsd	Edgar Link	pending
surg-20231231_lab.xml	Edgar Link	unprocessable
surg-20231231_pre.xml	Edgar Link	unprocessable
surg-20231231_cal.xml	Edgar Link	unprocessable
surg-20231231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SURG
SurgePays, Inc. Stock $surg

2024 Q1 Form 10-K Financial Statement

#000149315224009661 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SURG SurgePays, Inc. Stock $surg

2024 Q1 Form 10-K Financial Statement

#000149315224009661 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SURG
SurgePays, Inc. Stock $surg